《Table 1 Modified UCSF down-staging criteria》

《Table 1 Modified UCSF down-staging criteria》   提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《Hepatocellular carcinoma-time to take the ticket》


  1. 获取 高清版本忘记账户?点击这里登录
  1. 下载图表忘记账户?点击这里登录

The data from the global investigation of therapeutic decision in HCC and of treatment with sorafenib(referred to as“GIDEON”)[10]have shown that the combination of TACE and sorafenib has a beneficial effect on overall survival in patients with advanced disease.The START trial[11]also supports the abovementioned finding.The SPACE trial[12]tried this combination on the Barcelona stage B HCC and did not find any difference compared to using TACE alone.Even though few of the latest studies[13]have shown benefit,further investigation is required,and feasibility of this combination for down-staging needs to be evaluated.